H 101

Drug Profile

H 101

Alternative Names: H101; Oncorine; rAd5 H101

Latest Information Update: 24 Mar 2015

Price : $50

At a glance

  • Originator Shanghai Sunway Biotech
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action P53 gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Head and neck cancer
  • Phase II Lung cancer
  • Clinical Phase Unknown Liver cancer; Malignant pleural effusion; Pancreatic cancer; Peritoneal cancer
  • No development reported Bone cancer

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top